These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 28822797)

  • 21. Response to Imatinib therapy is inferior for e13a2
    Greenfield G; McMullan R; Robson N; McGimpsey J; Catherwood M; McMullin MF
    BMC Hematol; 2019; 19():7. PubMed ID: 31073408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
    Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Dyagil I; Glushko N; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Reilly L; Jeynes-Ellis A; Leip E; Bardy-Bouxin N; Hochhaus A; Brümmendorf TH
    J Clin Oncol; 2018 Jan; 36(3):231-237. PubMed ID: 29091516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distribution of
    Owojuyigbe TO; Durosinmi MA; Bolarinwa RAA; Salawu L; Akinola NO; Ademosun AA; Bosede OT
    Indian J Hematol Blood Transfus; 2020 Oct; 36(4):646-651. PubMed ID: 33100706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostic significance.
    Gui X; Zhang Y; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
    Leuk Lymphoma; 2015; 56(12):3343-7. PubMed ID: 25962435
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Pagani IS; Dang P; Kommers IO; Goyne JM; Nicola M; Saunders VA; Braley J; White DL; Yeung DT; Branford S; Hughes TP; Ross DM
    Haematologica; 2018 Dec; 103(12):2026-2032. PubMed ID: 29976745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.
    Eskazan AE; Sadri S; Keskin D; Ayer M; Kantarcioglu B; Demirel N; Aydin D; Aydinli F; Yokus O; Ozunal IE; Berk S; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):804-811. PubMed ID: 28847475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis.
    Chen K; Ruan Y; Tian K; Xiong P; Xia N; Li J; Huang W; Cao F; Chen Q
    Front Oncol; 2022; 12():841546. PubMed ID: 35223524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
    Marcé S; Xicoy B; García O; Cabezón M; Estrada N; Vélez P; Boqué C; Sagüés M; Angona A; Teruel-Montoya R; Ferrer-Marín F; Amat P; Hernández-Boluda JC; Ibarra MM; Anguita E; Cortés M; Fernández-Ruiz A; Fontanals S; Zamora L; On Behalf Of The Grupo Español de Leucemia Mieloide Crónica Gelmc
    J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
    Stella S; Zammit V; Vitale SR; Pennisi MS; Massimino M; Tirrò E; Forte S; Spitaleri A; Antolino A; Siracusa S; Accurso V; Mannina D; Impera S; Musolino C; Russo S; Malato A; Mineo G; Musso M; Porretto F; Martino B; Di Raimondo F; Manzella L; Vigneri P; Stagno F
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of BCR-ABL gene variants in patients of chronic myeloid leukemia.
    Amin H; Ahmed S
    Open Med (Wars); 2021; 16(1):904-912. PubMed ID: 34183996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients.
    Qin YZ; Jiang Q; Jiang H; Lai YY; Zhu HH; Liu YR; Jiang B; Huang XJ
    Medicine (Baltimore); 2016 Jan; 95(2):e2486. PubMed ID: 26765457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Significance of Transcript-Type
    Molica M; Abruzzese E; Breccia M
    Mediterr J Hematol Infect Dis; 2020; 12(1):e2020062. PubMed ID: 32952973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib.
    Popovici C; Cailleres S; David M; Lafage-Pochitaloff M; Sainty D; Mozziconacci MJ
    Leuk Lymphoma; 2005 Sep; 46(9):1375-7. PubMed ID: 16109618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-time quantitative PCR: a reliable molecular diagnostic and follow-up tool for 'minimal residual disease' assessment in chronic myeloid leukemia.
    Azad NA; Shah ZA; Pandith AA; Rasool R; Jeelani S
    Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30054431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia.
    Martínez-Castillo M; Gómez-Romero L; Tovar H; Olarte-Carrillo I; García-Laguna A; Barranco-Lampón G; De la Cruz-Rosas A; Martínez-Tovar A; Hernández-Zavala A; Córdova EJ
    Leuk Res; 2023 Aug; 131():107325. PubMed ID: 37302352
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Meza-Espinoza JP; Vásquez-Jiménez EA; Barajas-Torres RL; Magaña-Torres MT; González-García JR
    Ann Clin Lab Sci; 2019 Nov; 49(6):703-709. PubMed ID: 31882420
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate.
    Kaygusuz Atagunduz I; Toptas T; Deniz R; Kara O; Eser A; Sezgin A; Ozgumus T; Gecgel F; Firatli Tuglular T
    Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):120-125. PubMed ID: 28082113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.
    McCarron SL; Langabeer SE; Bolger K; Haslam K; Crampe M; Kelly J; Morrell R
    Med Oncol; 2015 Feb; 32(2):452. PubMed ID: 25579165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations.
    Inokuchi K; Nakayama K; Tauchi T; Takaku T; Yokose N; Yamaguchi H; Kumagai T; Komatsu N; Ohyashiki K
    Leuk Res; 2018 Feb; 65():74-79. PubMed ID: 29310021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.